Adagene Inc. ADAG

Company Overview

Adagene Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The company operates within the biotechnology and oncology sectors, with a strategic emphasis on precision immunotherapy and next-generation antibody engineering. Adagene’s primary business activities center on developing monoclonal antibodies and related therapeutics designed to improve efficacy while reducing toxicity in cancer treatment. Its core technology platforms include Dynamic Precision Library (DPL) and NEObody, which are used to engineer antibodies with enhanced selectivity and conditional activation properties. Revenue generation has historically been derived primarily from collaboration agreements, licensing arrangements, and research partnerships, as the company remains in the clinical development stage and does not yet generate commercial product revenue.

Adagene was founded in 2011 and has evolved from an antibody discovery company into a clinical-stage immuno-oncology developer with operations spanning the United States and China. The company has pursued a differentiated strategy centered on masking and activation technologies intended to address limitations associated with conventional checkpoint inhibitors and antibody therapeutics. Adagene became publicly listed on the NASDAQ under the ticker ADAG in 2021. Its development programs target solid tumors and hematologic malignancies, positioning the company within the broader market for precision oncology and immune-modulating therapies.